| From: tktrimbath | 5/21/2024 11:17:47 AM | | | | | | Sold my house. Bought a more affordable one.
Bought a bit of:
$GERN
(The longer story is at https://trimbathcreative.net/2024/05/17/time-to-buy-but-what/)
|
| | Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: tktrimbath | 6/28/2024 8:19:13 PM | | | | | | My mid-year review of GERN
INTRO Here's my semi-annual exercise to see if I remember why I own the stocks I own, and so I can check back and see if their stories have changed. I post in case it helps others too.
Geron
GERN (market cap is $2.52B was $1.15B)
Geron (GERN) has been working on highly innovative biotech for decades. Decades! Finally, the FDA has officially approved Geron's blood cancer treatment. They will probably start trying to treat other types of cancer, too. One estimate is that the treatment will cost over $100,000 which is large compared to many drugs, but is meeting an unmet need, and it may be a lower overall cost. One bit of specifity is that patients may now experience "24 weeks of freedom from the burden of red blood cell transfusions". (https://trimbathcreative.net/2024/06/07/geron-approved/)
Years, decades ago, Geron had a diversified portfolio of innovative and somewhat controversial treatments that could fight cancer by convincing certain cells to die, and fight auto-immune disorders by allowing certain cells to live. From that broad range of possibilities they've narrowed down to blood cancer.
The good news for stockholders is that within the previous six months the stock has risen from ~$2 to ~$5. Such news can generate greater premiums, but dilution has so reduced the value of the shares that the premuim may already be built in.
If the treatment can be applied to other ailments, then a multiplier may be appropriate, but the investing market may wait to see if the medical industry accepts and encourages its use.
This is also the era of hyperbolic claims of price appreciation. If there is irrational exuberance, I may sell at least some shares.
My experience with the first occurrence of Dendreon (DNDN, trimbathcreative.net dampens my enthusiasm. They had an FDA-approved cancer vaccine, were actively undermined, the bad guys were found guilty, but the shareholders lost their money, or at least I did. Hopefully, that won't happen this time.
DISCLOSURE LTBH since 1999 and continuing to hold. I bought more after selling my house. I could buy more, but I expect I'll wait until I hear about Geron's plans for expansion.
(Other commentary and stocks at: trimbathcreative.net
& from my One Company One Story series on YouTube youtu.be ) |
| | Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| From: Savant | 12/23/2024 11:28:36 AM | | | | | | Needham & Company LLC reiterated their buy rating on shares of Geron ( NASDAQ:GERN – Free Report) in a research note released on Friday morning, Benzinga reports. Needham & Company LLC currently has a $6.00 price objective on the biopharmaceutical company’s stock.
Several other research analysts have also commented on the company. Barclays upgraded Geron to a “strong-buy” rating in a research report on Friday, November 29th. HC Wainwright reissued a “buy” rating and set a $9.00 target price on shares of Geron in a report on Tuesday, December 10th. Leerink Partners initiated coverage on shares of Geron in a report on Monday, September 9th. They issued an “outperform” rating and a $7.00 price target for the company. Leerink Partnrs raised shares of Geron to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Scotiabank initiated coverage on shares of Geron in a report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eight have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.15.
Geron’s (GERN) Buy Rating Reiterated at Needham & Company LLC - Defense World |
| | Geron Corp. | Stock Discussion ForumsShare | RecommendKeepReplyMark as Last Read |
|
| |
